Monopar Therapeutics: director Christopher M. Starr sold 8,400 shares

What happened

• Christopher M. Starr, a director, exercised options to acquire 8,400 shares at $0.01 per share for $42 and disposed of 8,400 shares in open-market transactions on Oct 1, 2026, for a total of $659,386.
• The sales are reported as 4,631 shares at a weighted average price of $78.09 ($361,635), 2,970 shares at a weighted average price of $78.82 ($234,095), and 799 shares at a weighted average price of $79.67 ($63,656). The Form 4 also reports a derivative disposition of 8,400 shares at $0.00 (code M).

Key details

• Transaction date: Oct 1, 2026.
• Exercise (code M): acquired 8,400 shares at $0.01 per share for $42.
• Sales (code S): 4,631 shares at weighted avg $78.09 for $361,635; 2,970 shares at weighted avg $78.82 for $234,095; 799 shares at weighted avg $79.67 for $63,656.
• Weighted average price ranges (per footnotes): 4,631-share range $77.50–$78.49 (F4); 2,970-share range $78.50–$79.49 (F5); 799-share range $79.50–$80.01 (F6). The filer will provide per-share sale-price details on request.
• Footnotes: sale effected pursuant to a Rule 10b5-1 plan executed May 28, 2026 (F1); options were originally granted Feb 20, 2017 with a stated vesting schedule (F2); some shares are held in the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as trustee (F3).
• Shares owned after the transaction: not stated in the Form 4.
• Filing date: Oct 5, 2026 (reporting transactions on Oct 1, 2026); filing timeliness not indicated.

Why it may matter

• The Form 4 shows an option exercise and simultaneous market sales of the same number of shares, consistent with a cashless exercise and immediate disposition.
• The open-market sales were made under a Rule 10b5-1 plan (May 28, 2026).
• A filing does not show why the insider traded or why the company acted.